JANX
Janux Therapeutics, Inc.14.65
-0.47-3.11%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
881.17MP/E (TTM)
-Basic EPS (TTM)
-1.67Dividend Yield
0%Recent Filings
10-K
FY2025 results
Janux Therapeutics posted FY2025 net losses of $113.6M, up from $69.0M in FY2024, driven by ramped R&D spend to $125.9M amid Phase 1 expansions for JANX007 (PSMA-TRACTr) and JANX008 (EGFR-TRACTr), while Merck collaboration revenue dipped to $10.0M. Q4 momentum shone in December 2025 data releases: JANX007 showed durable PSA reductions and rPFS of 7.9-8.9 months across QW/Q2W cohorts in taxane-naïve mCRPC, with grade 1-2 CRS confined to cycle 1; JANX008 launched Phase 1a expansions in select solid tumors post-dose escalation. Cash swelled to $967M on $779M from offerings, funding runway past 2027. Q4 accelerated clinical readouts. Clinical failures could stall momentum.
8-K
2025 results, BMS deal, pipeline updates
Janux Therapeutics reported full-year 2025 net loss of $157.7M, up from $69.0M in 2024, driven by R&D expenses doubling to $125.9M amid clinical advances. Cash reserves stood at $966.6M year-end, bolstered by a January 2026 BMS deal yielding $50M upfront. Pipeline progressed with JANX007 showing 7.9-8.9 month median rPFS in mCRPC. Leadership strengthened via new CMO hire.
8-K
Janux-BMS tumor therapy deal
Janux Therapeutics inked an exclusive worldwide license deal with Bristol Myers Squibb on January 21, 2026, for a novel tumor-activated T-cell engager targeting a solid tumor antigen. BMS pays $15M upfront, $35M near-term milestone, up to $785M total milestones, plus high-single to low-double digit royalties. Janux handles preclinical to IND; BMS takes over after. Collaboration hinges on BMS efforts.
10-Q
Q3 FY2025 results
Janux narrowed Q3 net losses to $24.3M from $28.1M y/y, thanks to $10M Merck milestone revenue—up from $0.4M—offset by R&D ramp to $34.6M (from $18.6M) on manufacturing and JANX007/8 progress. Interest income swelled to $10.9M (from $7.8M), narrowing the operating loss slightly. Cash and equivalents fell to $48.4M with short-term investments at $940.6M (total liquidity ~$989M), burning $53.7M operationally YTD while funding R&D. No debt. Stock-based comp drove most of the gap between operating and net losses. Clinical setbacks could stall the pipeline.
8-K
Q3 loss narrows, cash strong
Janux Therapeutics reported Q3 2025 net loss of $24.3 million, narrower than $28.1 million last year, while R&D expenses doubled to $34.6 million amid JANX007 and JANX008 Phase 1 enrollment. Cash pile stands at $989 million, down from $1.03 billion year-end 2024. Updates due Q4 2025. Balance sheet funds pipeline push.
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CTMX
CytomX Therapeutics, Inc.
4.25+0.12
GNLX
Genelux Corporation
4.10+0.02
IMTX
Immatics N.V.
10.09+0.11
LVTX
LAVA Therapeutics N.V.
1.74+0.00
MRKR
Marker Therapeutics, Inc.
1.27-0.12
MRSN
Mersana Therapeutics, Inc.
29.05+0.46
SNSE
Sensei Biotherapeutics, Inc.
8.08+0.19
TCRX
TScan Therapeutics, Inc.
0.95-0.01
TNGX
Tango Therapeutics, Inc.
8.96-0.16